LYRA — Lyra Therapeutics Share Price
0.000.00%
Last trade - 00:00- $310.07m
- $207.31m
- $1.56m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.47 | ||
| Price to Tang. Book | 3.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 199.02 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -54.57% | ||
| Return on Equity | -73.67% | ||
| Operating Margin | -4308.09% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.28 | 1.36 | 1.56 | 1.38 | 0.78 | 4.6% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lyra Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of therapies for the localized treatment of patients with chronic rhinosinusitis (CRS). The Company has two investigational product candidates, LYR-210 and LYR-220, in late-stage development for CRS, a prevalent inflammatory disease of the paranasal sinuses that leads to debilitating symptoms and significant morbidities. LYR-210 and LYR-220 are bioresorbable nasal implants designed to be administered in a brief, in-office procedure and are intended to deliver six months of continuous mometasone furoate drug therapy to the sinonasal passages. LYR-210 is designed for surgically naive patients and is being evaluated in the ENLIGHTEN Phase III clinical program, while LYR-220, is being evaluated in the BEACON Phase II clinical trial in patients who have recurrent symptoms despite having had prior ethmoid sinus surgery.
Directors
- Maria Palasis PRE (56)
- Jason Cavalier CFO (48)
- Pamela Nelson SVP (51)
- Corinne Noyes SVP (53)
- Robert Richard SVP
- Michael Altman IND (39)
- Edward Anderson IND (71)
- C. Ann Merrifield IND (70)
- Konstantin Poukalov IND (35)
- W. Bradford Smith IND (65)
- Nancy Snyderman IND (69)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- November 21st, 2005
- Public Since
- May 1st, 2020
- No. of Shareholders
- 68
- No. of Employees
- 88
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 59,743,123
- Address
- 480 Arsenal Way, WATERTOWN, 02472
- Web
- https://lyratherapeutics.com/
- Phone
- +1 6173734600
- Auditors
- BDO USA, LLP
Upcoming Events for LYRA
Lyra Therapeutics Inc Annual Shareholders Meeting
Lyra Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Lyra Therapeutics Inc Earnings Release
Similar to LYRA
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Lyra Therapeutics share price?
As of Today at 19:13 UTC, shares in Lyra Therapeutics are trading at $5.19. This share price information is delayed by 15 minutes.
How has the Lyra Therapeutics share price performed this year?
Shares in Lyra Therapeutics last closed at $5.19 and the price had moved by +156.93% over the past 365 days. In terms of relative price strength the Lyra Therapeutics share price has outperformed the S&P500 Index by +113.81% over the past year.
What are the analyst and broker recommendations for Lyra Therapeutics?
The overall consensus recommendation for Lyra Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Lyra Therapeutics dividend yield?
Lyra Therapeutics does not currently pay a dividend.
Does Lyra Therapeutics pay a dividend?
Lyra Therapeutics does not currently pay a dividend.
When does Lyra Therapeutics next pay dividends?
Lyra Therapeutics does not currently pay a dividend.
How do I buy Lyra Therapeutics shares?
To buy shares in Lyra Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lyra Therapeutics?
As of the previous close price of $5.19, shares in Lyra Therapeutics had a market capitalisation of $310.07m.
Where are Lyra Therapeutics shares listed?
Here are the trading details for Lyra Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: LYRA
What kind of share is Lyra Therapeutics?
Based on an overall assessment of its quality, value and momentum Lyra Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lyra Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Lyra Therapeutics is $12.00. That is 131.21% above the last closing price of $5.19.
Analysts covering Lyra Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.01 for the next financial year.
What is the trend in the Lyra Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lyra Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +22.73%.
As of the last closing price of $5.19, shares in Lyra Therapeutics were trading +21.99% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lyra Therapeutics PE Ratio?
The Lyra Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lyra Therapeutics?
Lyra Therapeutics' management team is headed by:
- Maria Palasis - PRE
- Jason Cavalier - CFO
- Pamela Nelson - SVP
- Corinne Noyes - SVP
- Robert Richard - SVP
- Michael Altman - IND
- Edward Anderson - IND
- C. Ann Merrifield - IND
- Konstantin Poukalov - IND
- W. Bradford Smith - IND
- Nancy Snyderman - IND